Enterprise record

Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacet

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:810631da-42e1-450b-a8db-7d602d72ce6dVersion: public-1As of: unavailable

13 published Claims2 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 28, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 28, 2026

    Supports 5 claims
    • Legal Name: Tenaya Therapeutics, Inc. · Claim reviewed: Sep 28, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 28, 2026
    • Published Fact: US · Claim reviewed: Sep 28, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 28, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 28, 2026

  2. Tenaya Therapeutics, Inc. DEF 14A 2026-04-16

    sec proxy · Source published: Apr 16, 2026 · Retrieved: Apr 25, 2026

    Supports 8 claims
    • Leadership Role: Amy Burroughs, M.B.A.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Catherine Stehman-Breen, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Deepak Srivastava, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Faraz Ali, M.B.A.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Jeffrey T. Walsh, M.B.A.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: June Lee, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Karah Parschauer, J.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: R. Sanders Williams, M.D.: Director · Claim reviewed: Sep 28, 2026